UPDATE: Cantor Fitzgerald Initiates Hold, $15 PT on ImmunoGen; In Need of Additional Catalyst

Cantor Fitzgerald initiates its rating on ImmunoGen

with a Hold rating and a price target of $15. Cantor Fitzgerald comments, "ImmunoGen is approaching commercial revenue via a partnership with Roche, and this is a solid positive for the stock. However, much of the good news is in the valuation and another catalyst is needed for greater appreciation, in our view." IMGN closed at $15 on Wednesday.